HIV Fight Falters: Experts Fear Setback as US Shifts Strategy

Concerns are mounting among experts that the US is risking hard-won gains in the fight against HIV, even as the epidemic's end appears within reach. The recent shift away from the comprehensive PEPFAR program towards bilateral agreements with individual countries is a primary driver of this apprehension.

Independent analyses of PEPFAR data reveal significant disruptions beyond stable treatment numbers. HIV testing has declined by 17%, and the number of people starting PrEP has dropped by 33%. Critically, the number of healthcare workers providing HIV services has decreased by 24%.

The decline in infant testing, diagnosis, and treatment is particularly alarming, given the high mortality rates for infants with HIV. Reports show drastic drops in pediatric HIV treatment and testing figures, with the State Department attributing this to program success, a claim met with skepticism by experts.

Furthermore, the transition to country-specific agreements, potentially influenced by resource extraction interests, threatens the robust data collection that made PEPFAR effective. This move also coincides with layoffs impacting critical global health workforces at agencies like USAID and the CDC, raising accountability issues for taxpayer-funded initiatives.

While the speed of the transition to country leadership is noted as a remarkable achievement, experts caution that the pace risks outstripping the necessary systems for safe management. The dismantling of PEPFAR's accountability structures could make it harder for US taxpayers to oversee billions in funding and to identify effective programs.